Vitamin D status and viral response to therapy in hepatitis C infected children

Table 1 Demographic and clinical data for the studied groups and control

	A	B	Total	Control	P value
	(n = 31)	(n = 29)	(n = 60)	(n = 28)
Age (yr)	11.1 ± 2.178	11.043 ± 2.882	11.17 ± 2.293	9.35 ± 3.24	0.445
Duration of illness (yr)	3.4 ± 1.984	3.123 ± 1.688	3.262 ± 1.832	-	0.563
BMI (kg/m2)	20.81 ± 4.29	20.28 ± 3.13	20.54 ± 3.73	21.21 ± 2.34	0.588
Male/female	23/8 (74.1%/25.8%)	20/9 (68.9%/31.1%)	43/17 (71.6%/28.3 %)	17/13 (60.7%/46.4%)	0.284
Blood transfusion, n (%)	16 (51.6)	16 (55.1)	32 (53.3)	-	0.602
Positive family history of HCV	8 (25.8)	1 (3.4)	9 (15.0)	-	0.051
Jaundice, n (%)	19 (61.2)	13 (44.8)	32 (53.3)	-	0.098
Fever, n (%)	9 (29.0)	9 (31.0)	18 (30.0)	-	0.611
History of bleeding, n (%)	17 (54.8)	16 (55.1)	33 (55.0)	-	0.501

¹Significance total vs control. No significant difference between group A and B. Data are presented as the mean ± SD or number (%) as appropriate. BMI: Body mass index.